Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siponimod and COVID-19 mRNA Vaccines in SPMS
NCT04792567Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of siponimod in secondary-progressive multiple sclerosis (SPMS), sponsored by Novartis. Started Apr 2021; status: completed.
02
Drugs
siponimod
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT04792567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04792567.